Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

STADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer.

Authors

Institutions

Publication Details

Journal
European Urology
Published
2025-08-15
DOI
https://doi.org/10.1016/j.eururo.2025.07.019
Citations
3
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
4.56
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

Nicolas Demogeot, Bernard Dubray, Jean‐Michel Hannoun‐Lévi, Antoine Simon et al.
3 citations
European Urology
Prostate Cancer Treatment and Research
4.56
article

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

Nicolas Demogeot, Bernard Dubray, Jean‐Michel Hannoun‐Lévi, Antoine Simon, Nicolas Bauer, Yazid Belkacémi, G. Calais, Paul Sargos, D. Azria, Jonathan Khalifa, Stéphane Supiot, V. Beckendorf, Christophe Hennequin, Julia Salleron, V. Marchesi, Gauthier Bouche, Nassim Sahki, P. Pommier, S. Guérif, Jacques Cretin, Caroline Léger, R. de Crevoisier
article en
3 citations

Abstract

STADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer.

European UrologyVol. 88(5)
Inserm (FR), Université Paris-Est Créteil (FR), Sorbonne Université (FR), Centre de Radiothérapie Bayard (FR), Centre Hospitalier Universitaire de Tours (FR), Institut de Cancérologie de Lorraine (FR), Hôpital Bretonneau (FR), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Centre Eugène Marquis (FR), Centre Hospitalier Universitaire de Poitiers (FR), Hôpital Émile-Roux (FR), Institut de Cancérologie de Bourgogne (FR), Pitié-Salpêtrière Hospital (FR), Institut Claudius Regaud (FR), Institut Bergonié (FR), Institut de Recherche en Hématologie et Transplantation (FR), Institut de Recherche en Cancérologie de Montpellier (FR), UniCancer Group (FR), Hôpital Saint-Louis (FR), Centre Antoine Lacassagne (FR), Laboratoire de Génétique Cellulaire (FR), Institut Jean Godinot (FR), Institut Mondor de Recherche Biomédicale (FR), Centre Henri Becquerel
Openalex Percentile: Top 5%
Prostate Cancer Treatment and Research
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.